scholarly article | Q13442814 |
P50 | author | Marcelo Wolff | Q55523651 |
Jean-William Pape | Q67590873 | ||
Denis Padgett | Q83392975 | ||
Catherine C. McGowan | Q83393370 | ||
Peter Francis Rebeiro | Q42707320 | ||
P2093 | author name string | Sandra Wagner Cardoso | |
Bryan E Shepherd | |||
Juan Echevarria | |||
Carina Cesar | |||
Juan Sierra-Madero | |||
Claudia Cortés | |||
Caribbean, Central and South America Network for HIV Epidemiology | |||
P2860 | cites work | Predictors of failure of first-line antiretroviral therapy in HIV-infected adults: Indian experience | Q50145094 |
Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen ( | Q50803241 | ||
Confounding by indication | Q71502678 | ||
Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals | Q22242705 | ||
Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean | Q28749991 | ||
Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America | Q33598309 | ||
Correcting mortality for loss to follow-up: a nomogram applied to antiretroviral treatment programmes in sub-Saharan Africa | Q33803701 | ||
Outcomes after virologic failure of first-line ART in South Africa | Q33985234 | ||
Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland | Q34113515 | ||
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study | Q34474961 | ||
Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies | Q34667707 | ||
Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region | Q34804309 | ||
Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database | Q34977431 | ||
Splines for trend analysis and continuous confounder control. | Q35335098 | ||
Long-term antiretroviral treatment outcomes in seven countries in the Caribbean | Q35823246 | ||
A causal framework for understanding the effect of losses to follow-up on epidemiologic analyses in clinic-based cohorts: the case of HIV-infected patients on antiretroviral therapy in Africa | Q35963111 | ||
Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. | Q36661756 | ||
National review of first treatment change after starting highly active antiretroviral therapy in antiretroviral-naïve patients | Q36802662 | ||
Cohort Profile: Caribbean, Central and South America Network for HIV research (CCASAnet) collaboration within the International Epidemiologic Databases to Evaluate AIDS (IeDEA) programme | Q36936569 | ||
Early mortality and cause of deaths in patients using HAART in Brazil and the United States | Q37215053 | ||
Risk factors associated with virologic failure in HIV- infected patients receiving antiretroviral therapy at a public hospital in Peru | Q37481106 | ||
Cohort studies: to what extent can they inform treatment guidelines? | Q37649350 | ||
Management of antiretroviral failure and resistance in developing countries | Q37667831 | ||
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis | Q37982191 | ||
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics | Q37985378 | ||
Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy | Q38400338 | ||
Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients | Q38448897 | ||
Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda | Q38869763 | ||
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone | Q39422861 | ||
Incidence of modifying or discontinuing first HAART regimen and its determinants in a cohort of HIV-infected patients from Rio de Janeiro, Brazil | Q39851943 | ||
Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study | Q41661280 | ||
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens | Q43683920 | ||
Impact of antiretroviral regimen switches on adherence | Q44198906 | ||
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009. | Q44982299 | ||
Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings | Q45774389 | ||
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries | Q46391119 | ||
Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. | Q46425339 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | virology | Q7215 |
Caribbean | Q664609 | ||
anti-retroviral agent | Q50430310 | ||
P304 | page(s) | 102-110 | |
P577 | publication date | 2016-01-01 | |
P1433 | published in | Journal of Acquired Immune Deficiency Syndromes | Q6294722 |
P1476 | title | Clinical and Virologic Outcomes After Changes in First Antiretroviral Regimen at 7 Sites in the Caribbean, Central and South America Network | |
P478 | volume | 71 |
Q33834625 | A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy |
Q52661543 | Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America. |
Q37653463 | Effectiveness and Risk Factors for Virological Outcome of Raltegravir-Based Therapy for Treatment-Experienced HIV-Infected Patients. |
Q38377004 | Effectiveness of second-line antiretroviral therapy: the impact of drug switches |
Q90283351 | HIV Care continuum Outcomes: Can Ethiopia Meet the UNAIDS 90-90-90 Targets? |
Q58769869 | Immunological failure in HIV-infected adults from 2003 to 2015 in Southwest Ethiopia: a retrospective cohort study |
Search more.